The a2 Milk Company wishes to advise of a change in the role of a senior member of the Company’s senior leadership team.
Chief Scientific Officer
Dr Andrew Clarke will step down from his current executive role as Chief Scientific Officer, and assume a new part time role as Chief Scientific Advisor to the CEO for an initial term of three years, effective from 1 August 2018.
In conjunction with the change to Andrew’s position, the Company intends to establish two new roles in the complementary areas of clinical and commercial science.
These planned changes to the Company’s science function will both broaden the skill set and resources relating to this function and accommodate Andrew’s personal plans for the future.
Andrew has made a very significant contribution to the Company over the past 15 years, both in his current role of CSO and in earlier roles when the Company was in its early stages of development. The Company thanks Andrew for his outstanding service and looks forward to his ongoing involvement and contribution into the future.
A PDF version of this announcement can be found here.